Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study

Iavarone, M.; Tosetti, Giulia; Facchetti, F.; Topa, Matilde; Er, Joey Ming; Hang, Shou Kit; Licari, Debora; Lombardi, Andrea; D’Ambrosio, Roberta; Degasperi, Elisabetta; Loglio, Alessandro; Oggioni, Chiara; Perbellini, R.; Caccia, R.; Bandera, Alessandra; Gori, Andrea; Ceriotti, Ferruccio; Scudeller, Luigia; Bertoletti, Antonio; Lampertico, Pietro

doi:10.1016/j.dld.2022.09.010

Cited by 17 publications

(29 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Given their vulnerability profile in cases of SARS-CoV-2 infection, such vaccines have been strictly recommended in LT recipients and patients with CLD, with priority to cirrhotic patients and those with HCC or ALD (Figure 1 )[ 90 - 92 ]. In this setting, vaccines have found to be generally safe[ 93 - 95 ], although sporadic cases of post-vaccinal ALI are reported, with predominantly hepatocellular and immune-mediated injury due to a probable aberrant response of the immune system after vaccine stimulation[ 96 ].…”

Section: Chronic Hepatitis and Covid-19 Clinical Outcomesmentioning

confidence: 99%

“…Anti-SARS-CoV-2 vaccines are able to determine both a T-cell and a humoral response, stimulating the production of antibodies directed against the Spike protein (seroconversion) and neutralizing antibodies[ 101 , 102 ]. Prospective studies compared the immunological response induced by a full course of mRNA vaccines and/or viral vector vaccines in patients with liver cirrhosis and controls[ 93 - 95 ]. Almost all patients with liver cirrhosis showed production of anti-Spike antibodies and a neutralizing antibody activity, similar to patients without liver cirrhosis[ 93 ].…”

Section: Chronic Hepatitis and Covid-19 Clinical Outcomesmentioning

confidence: 99%

See 1 more Smart Citation

Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination

Nevola¹,

Criscuolo²,

Beccia³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

Since the first identification in December of 2019 and the fast spread of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection, it has represented a dramatic global public health concern. Though affecting mainly the respiratory system, SARS-CoV-2 disease, defined as coronavirus disease 2019 (COVID-19), may have a systemic involvement leading to multiple organ dysfunction. Experimental evidence about the SARS-CoV-2 tropism for the liver and the increasing of hepatic cytolysis enzymes during infection support the presence of a pathophysiological relationship between liver and SARS-CoV-2. On the other side, patients with chronic liver disease have been demonstrated to have a poor prognosis with COVID-19. In particular, patients with liver cirrhosis appear extremely vulnerable to infection. Moreover, the etiology of liver disease and the vaccination status could affect the COVID-19 outcomes. This review analyzes the impact of the disease stage and the related causes on morbidity and mortality, clinical outcomes during SARS-CoV-2 infection, as well as the efficacy of vaccination in patients with chronic liver disease.

show abstract

Section: Chronic Hepatitis and Covid-19 Clinical Outcomesmentioning

confidence: 99%

Section: Chronic Hepatitis and Covid-19 Clinical Outcomesmentioning

confidence: 99%

Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination

Nevola¹,

Criscuolo²,

Beccia³

et al. 2023

World J Gastroenterol

View full text Add to dashboard Cite

show abstract

“…We would like to discuss the article, entitled “Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study”, which was recently published in your journal [1] .” In this article, the authors Iavarone et al. evaluated the incidence of breakthrough infections, adverse events, and humoral and cellular responses in comparison to healthy controls (AEs).…”

mentioning

confidence: 99%

“…evaluated the incidence of breakthrough infections, adverse events, and humoral and cellular responses in comparison to healthy controls (AEs). Spike-specific T-cell responses and antibodies against spike- and nucleocapsid-protein (anti-S and anti-N) were measured at baseline, 21 days after the first and second doses, and during follow-up [1] . Iavarone et al.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis

Kleebayoon

Wiwanitkit

2023

Digestive and Liver Disease

View full text Add to dashboard Cite

Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

Zhao,

Li,

Tian

et al. 2024

Cancer Medicine

View full text Add to dashboard Cite

BackgroundThe efficacy of coronavirus disease 2019 (COVID‐19) vaccines in preventing SARS‐CoV‐2 infection in patients with hepatocellular carcinoma (HCC) is not clear.MethodsFrom January 2022 to October 2022, patients diagnosed with HCC in a prospective, multicenter, observational cohort were analyzed.ResultsOne hundred and forty‐one patients with (n = 107) or without COVID‐19 vaccination (n = 34) were included. The number of patients with severe or very severe infection was relatively lower in the vaccinated group (3.7% vs. 11.8%, p = 0.096). Median infection‐free survival in the vaccinated group (14.0 vs. 8.3 months, p = 0.010) was significantly longer than that in the unvaccinated group. COVID‐19 vaccination (hazard ratio (HR) HR = 0.47), European Cooperative Oncology Group performance score = 0 (HR = 2.06), and extrahepatic spread (HR = 0.28) were found to be the independent predictive factors for infection‐free survival.ConclusionCOVID‐19 vaccines could effectively reduce the SARS‐Cov‐2 infection in patients with HCC.

show abstract

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis: A prospective single center study

Cited by 17 publications

References 27 publications

Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination

Impact of chronic liver disease on SARS-CoV-2 infection outcomes: Roles of stage, etiology and vaccination

Spike-specific humoral and cellular immune responses after COVID-19 mRNA vaccination in patients with cirrhosis

Efficacy and prognostic factors of COVID‐19 vaccine in patients with hepatocellular carcinoma: Analysis of data from a prospective cohort study

Contact Info

Product

Resources

About